

Amylyx Pharmaceuticals, Inc. (AMLX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001658551

Amylyx Pharmaceuticals, Inc.	
AMLX; healthcare	
Grade	D fourth fifth of 371 graded peers percentile 67.6; sampling error 2.5 points; lower is stronger
Rank	251 of 371
Profitability	D percentile 71.7
Solvency	B percentile 26.2
Growth and financing	D percentile 63.5
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$332.6M
Standard universe	outside revenue above \$1M and assets above \$10M
Warnings	short runway, degenerate inputs not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 3, 2026 220 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$27.22 2026-10-08; market equity \$3.0B
Price used in grade	None

D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Nov Jan Mar May Jul Sep

\$20 \$40

\$27.20

Rescans on file: D from Aug 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on

well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality. Our current pipeline is represented in the table below.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 71.7						
Gross profitability		0.0%	32.2%	95.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(8.1%)	(6.6%)	47.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 4
Solvency, sleeve percentile 26.2						
Twelve-month failure probability		0.10%	0.07%	57.5	248	2026-06-30
Altman Z double-prime		7.18	(0.31)	13.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		14.27x	2.96x	8.0	839	2025-12-31
Growth and financing, sleeve percentile 63.5						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(5.3%)	2.1%	62.4	704	2025-12-31
Net share issuance, one year		24.8%	2.5%	64.6	634	2026-02-23


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 4.7 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
246	Angiodynamics Inc. (ANGO)	66.2	D	fortress balance sheet
247	AIM ImmunoTech Inc. (AIM)	66.5	D	late filer, degenerate inputs, distress
248	Exagen Inc. (XGN)	66.8	D	dilution, fortress balance sheet
249	PTC Therapeutics, Inc. (PTCT)	67.0	D	
250	Cardiff Oncology, Inc. (CRDF)	67.3	D	short runway, fortress balance sheet
251	Amylyx Pharmaceuticals, Inc. (AMLX) <	67.6	D	short runway, degenerate inputs
252	U S Physical Therapy Inc. (USPH)	67.8	D	
253	American Shared Hospital Services (AMS)	68.1	D	late filer
254	Orchestra BioMed Holdings, Inc. (OBIO)	68.4	D	dilution, short runway, fortress balance sheet
255	Adaptive Biotechnologies Corp. (ADPT)	68.6	D	
256	Iridex Corp. (IRIX)	68.9	D	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	148.3%	8.0%	93
Distance from 52-week high	(31.4%)	(31.4%)	49
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(4.1%)	(1.0%)	42
Book value to price	0.08	0.28	23
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.70	(0.14)	93

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$49.3M
Operating cash flow, four quarters	-\$126.6M
Months of runway	4.7
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$42.8M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2025-12-31	2026-03-03	10-K	0001193125-26-086645
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$0	2025-12-31	2026-03-03	10-K	0001193125-26-086645
3	assets	us-gaap:Assets	\$332.6M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
4	net income	us-gaap:NetIncomeLoss	-\$144.7M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$123.3M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
6	assets	us-gaap:Assets	\$193.6M	2024-12-31	2026-03-03	10-K	0001193125-26-086645
7	current assets	us-gaap:AssetsCurrent	\$323.7M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
8	current liabilities	us-gaap:LiabilitiesCurrent	\$22.7M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$751.4M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
10	operating income	us-gaap:OperatingIncomeLoss	-\$153.3M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
11	book equity	us-gaap:StockholdersEquity	\$305.3M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
12	liabilities	us-gaap:Liabilities	\$27.4M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$87.4M	2024-12-31	2026-03-03	10-K	0001193125-26-086645
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$380.8M	2023-12-31	2025-03-04	10-K	0000950170-25-031309
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$22.2M	2022-12-31	2024-02-22	10-K	0000950170-24-018447
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$138,000	2025-12-31	2026-03-03	10-K	0001193125-26-086645
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$167.6M	2024-12-31	2026-03-03	10-K	0001193125-26-086645
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$157,000	2024-12-31	2026-03-03	10-K	0001193125-26-086645
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$11.9M	2023-12-31	2025-03-04	10-K	0000950170-25-031309
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2M	2023-12-31	2025-03-04	10-K	0000950170-25-031309
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$179.9M	2022-12-31	2024-02-22	10-K	0000950170-24-018447
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.5M	2022-12-31	2024-02-22	10-K	0000950170-24-018447
23	depreciation amortization	us-gaap:Depreciation	\$525,000	2025-12-31	2026-03-03	10-K	0001193125-26-086645
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$144.7M	2025-12-31	2026-03-03	10-K	0001193125-26-086645
25	income tax	us-gaap:IncomeTaxExpenseBenefit	\$46,000	2025-12-31	2026-03-03	10-K	0001193125-26-086645
26	current assets	us-gaap:AssetsCurrent	\$189.4M	2024-12-31	2026-03-03	10-K	0001193125-26-086645
27	current liabilities	us-gaap:LiabilitiesCurrent	\$28.4M	2024-12-31	2026-03-03	10-K	0001193125-26-086645
28	assets	us-gaap:Assets	\$517.5M	2023-12-31	2025-03-04	10-K	0000950170-25-031309
29	assets	us-gaap:Assets	\$391.5M	2022-12-31	2024-02-22	10-K	0000950170-24-018447
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	110,536,944	2026-02-23	2026-03-03	10-K	0001193125-26-086645
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,602,468	2025-02-28	2025-03-04	10-K	0000950170-25-031309